[1]
|
Klepin, H.D., Rao, A.V. and Pardee, T.S. (2014) Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults. Journal of Clinical Oncology, 32, 2541-2552. https://doi.org/10.1200/JCO.2014.55.1564
|
[2]
|
Pollyea, D.A., Bixby, D., Perl, A., et al. (2021) NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network, 19, 16-27.
|
[3]
|
白洁菲, 梅迪, 韩惠秀, 等. 综合老年学评估对老年急性髓系白血病患者的预后价值的单中心研究[J]. 中华血液学杂志, 2019, 40(3): 200-203.
|
[4]
|
汪少飞, 赵会英, 黄静, 等. 老年急性髓系白血病治疗进展[J]. 中国实验血液学杂志, 2017, 25(4): 1271-1274.
|
[5]
|
杨华, 牛建花, 朱成英, 等. 76例老年急性髓系AML(非APL)诱导化疗疗效及预后分析[J]. 中国实验血液学杂志, 2014, 22(4): 957-964.
|
[6]
|
Kantarjian, H. and O’Brien, S. (2010) Questions Regarding Frontline Therapy of Acute Myeloid Leukemia. Cancer, 116, 4896-4901. https://doi.org/10.1002/cncr.25281
|
[7]
|
Podoltsev, N.A., Stahl, M., Zeidan, A.M., et al. (2017) Selecting Initial Treatment of Acute Myeloid Leukemia in Older Adults. Blood Reviews, 31, 43-62. https://doi.org/10.1016/j.blre.2016.09.005
|
[8]
|
Thomas, X. (2017) The Management and Treatment of Acute Leu-kemias in the Elderly Population. Expert Review of Hematology, 10, 975-985. https://doi.org/10.1080/17474086.2017.1382345
|
[9]
|
崔高安. 阿糖胞苷在成人急性髓细胞白血病巩固化疗中的临床应用[J]. 当代医学, 2020, 26(11): 164-165.
|
[10]
|
Hajji, N., Mateos, S., Pastor, N., et al. (2005) Induction of Genotoxic and Cytotoxic Damage by Aclarubicin, a Dual Topoisomerase Inhibitor. Mutation Research: International Journal on Mutagenesis, Chromosome Breakage and Related Subjects, 583, 26-35. https://doi.org/10.1016/j.mrgentox.2005.01.012
|
[11]
|
Usuki, K., Urabe, A., Masaoka, T., et al. (2002) Efficacy of Granulocyte Colony-Stimulating Factor in the Treatment of Acute Myelogenous Leukaemia: A Multicentre Randomized Study. British Journal of Haematology, 116, 103-112.
https://doi.org/10.1046/j.1365-2141.2002.03251.x
|
[12]
|
Thomas, X., Raffoux, E., Renneville, A., et al. (2010) Which AML Subsets Benefit from Leukemic Cell Priming during Chemotherapy? Long-Term Analysis of the ALFA-9802 GM-CSF Study. Cancer, 116, 1725-1732.
https://doi.org/10.1002/cncr.24943
|
[13]
|
Wei, G., Ni, W., Chiao, J.W., et al. (2011) A Meta-Analysis of CAG (Cy-tarabine, Aclarubicin, G-CSF) Regimen for the Treatment of 1029 Patients with Acute Myeloid Leukemia and Myelo-dysplastic Syndrome. Journal of Hematology & Oncology, 4, Article No. 46. https://doi.org/10.1186/1756-8722-4-46
|
[14]
|
田婉露, 曾庆曙, 葛健, 等. CAG方案治疗急性白血病和高危骨髓增生异常综合征临床疗效观察[J]. 安徽医学, 2014, 35(7): 865-869.
|
[15]
|
Boddu, P.C., Kantarjian, H.M., Ravandi, F., et al. (2017) Characteristics and Outcomes of Older Patients with Secondary Acute Myeloid Leukemia According to Treatment Approach. Cancer, 123, 3050-3060.
https://doi.org/10.1002/cncr.30704
|
[16]
|
邓丽娟, 黎琰, 乔艳红, 等. 去甲基化药物在急性髓系白血病中的临床应用进展[J]. 中国新药与临床杂志, 2020, 39(6): 329-334.
|
[17]
|
Lübbert, M., Rüter, B.H., Claus, R., et al. (2012) A Multicenter Phase II Trial of Decitabine as First-Line Treatment for Older Patients with Acute Myeloid Leukemia Judged Unfit for Induction Chemotherapy. Haematologica, 97, 393-401.
https://doi.org/10.3324/haematol.2011.048231
|
[18]
|
Li, J., Chen, Y., Zhu, Y., et al. (2015) Efficacy and Safety of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia. Oncotarget, 6, 6448- 6458. https://doi.org/10.18632/oncotarget.3361
|
[19]
|
Xu, Q.Y. and Yu, L. (2020) Epigenetic Therapies in Acute Myeloid Leukemia: The Role of Hypomethylating Agents, Histone Deacetylase Inhibitors and the Combination of Hypomethylating Agents with Histone Deacetylase Inhibitors. Chinese Medical Journal (England), 133, 699-715. https://doi.org/10.1097/CM9.0000000000000685
|
[20]
|
Dombret, H., Seymour, J.F., Butrym, A., et al. (2015) International Phase 3 Study of Azacitidine vs Conventional Care Regimens in Older Patients with Newly Diagnosed AML with > 30% Blasts. Blood, 126, 291-299.
https://doi.org/10.1182/blood-2015-01-621664
|
[21]
|
Itzykson, R., Thépot, S., Berthon, C., et al. (2015) Azacitidine for the Treatment of Relapsed and Refractory AML in Older Patients. Leukemia Research, 39, 124-130. https://doi.org/10.1016/j.leukres.2014.11.009
|
[22]
|
Dinardo, C.D., Jonas, B.A., Pullarkat, V., et al. (2020) Aza-citidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. The New England Journal of Medicine, 383, 617-629. https://doi.org/10.1056/NEJMoa2012971
|
[23]
|
Yang, X. and Wang, J. (2018) Precision Therapy for Acute Myeloid Leukemia. Journal of Hematology & Oncology, 11, 3. https://doi.org/10.1186/s13045-017-0543-7
|
[24]
|
Schlenk, R.F., Weber, D., Fiedler, W., et al. (2019) Midostaurin Added to Chemotherapy and Continued Single-Agent Maintenance Therapy in Acute Myeloid Leukemia with FLT3-ITD. Blood, 133, 840-851.
https://doi.org/10.1182/blood-2018-08-869453
|
[25]
|
Serve, H., Krug, U., Wagner, R., et al. (2013) Sorafenib in Combination with Intensive Chemotherapy in Elderly Atients with Acute Myeloid Leukemia: Results from a Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology, 31, 3110-3118. https://doi.org/10.1200/JCO.2012.46.4990
|
[26]
|
Zhao, J.C., Agarwal, S., Ahmad, H., et al. (2021) A Review of FLT3 Inhibitors in Acute Myeloid Leukemia. Blood Reviews, 2021, Article ID: 100905. https://doi.org/10.1016/j.blre.2021.100905
|
[27]
|
Perl, A.E., Martinelli, G., Cortes, J.E., et al. (2019) Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3- Mutated AML. The New England Journal of Medicine, 381, 1728-1740. https://doi.org/10.1056/NEJMoa1902688
|
[28]
|
张瑜, 冶尕西, 陈卫川, 等. 陈卫川主任治疗老年急性白血病经验举隅[J]. 内蒙古中医药, 2018, 37(5): 20-21.
|
[29]
|
李昌桂, 周永明. 周永明治疗老年急性白血病临床经验[J]. 上海中医药大学学报, 2017, 31(2): 1-3.
|
[30]
|
王荣华, 陈信义, 李冬云, 等. 复方浙贝颗粒联合不同化疗方案对难治性急性白血病临床疗效的影响[J]. 北京中医药大学学报, 2014, 37(7): 458-462+475.
|
[31]
|
吴迪炯, 叶宝东, 沈一平, 沈建平, 林圣云, 胡致平, 俞庆宏, 郑智茵, 罗赟飞, 温晓文, 曾玉晓, 邵科钉, 张宇, 周郁鸿. 抗白延年汤联合小剂量化疗治疗老年初发急性髓系白血病疗效观察[J]. 中华中医药杂志, 2014, 29(9): 3012-3015.
|
[32]
|
郑丹丹, 孙伟玲, 周永明. 定清片对人白血病HL-60细胞增殖及凋亡的影响[J]. 世界中西医结合杂志, 2017, 12(8): 1037-1040.
|
[33]
|
Palmieri, R., Paterno, G., De Bellis, E., et al. (2020) Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. Cancers (Basel), 12, Article No. 120. https://doi.org/10.3390/cancers12010120
|
[34]
|
徐天娇. 微移植促进H-2半相合小鼠造血恢复的实验研究[D]: [硕士学位论文]. 上海: 中国人民解放军军事医学科学院, 2013.
|
[35]
|
Hong, M., Zhu, H., Sun, Q., et al. (2020) Decitabine in Combination with Low-Dose Cytarabine, Aclarubicin and G-CSF Tends to Improve Prognosis in Elderly Patients with High-Risk AML. Aging (Albany NY), 12, 5792-5811.
https://doi.org/10.18632/aging.102973
|